Glaxo places PR business for HIV drugs under review

Share this article:

GlaxoSmithKline has placed the PR business for its HIV medications franchise in review.
The incumbent agency, Chicagobased PCI Public Communications, is not participating in the review.
A GSK spokeswoman declined to comment on the review, citing corporate policy that "any of our agency dealings is confidential."

 

Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.